Sonia B. Kim

Sonia B. Kim

Auto-generated profile, based on publicly available information

Sonia B. Kim

Case Western Reserve University School of Medicine, Cleveland, Ohio; Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2025 in Ophthalmology
Verified
Journal Article
Open access
KAKevin C. Allan
Kevin C. Allan
JJJulia H. Joo
Julia H. Joo
SKSonia Kim
Sonia Kim
JSJacqueline Shaia
Jacqueline Shaia
DKDavid . Kaelber
David . Kaelber
ARAleksandra V. Rachitskaya
Aleksandra V. Rachitskaya
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been shown to exert neuroprotective and anti-inflammatory effects across multiple organ systems. This study investigated whether GLP-1RAs influence the risk for age-related ocular diseases. Retrospective cohort study. This study used an electronic health records platform of patients in the United States. Patients > 60 years with at least 5 years of ophthalmology follow-up and medication prescription documentation were included. There were 5 medication groups: GLP-1RA, metformin, insulin, statin, or aspirin users. Cohorts were propensity matched (1:1) on demographics and chronic disease risk factors. Outcomes of cataract, ocular hypertension, primary open-angle glaucoma, nonexudative age-related macular degeneration (AMD), and exudative AMD were compared 5 years after initial medication prescription. We then examined earlier time points within the 5-year period. Significance was defined as P < 0.05 with a hazard ratio (HR) threshold of > 1.1 or < 0.9. Of the 9669 patients taking GLP-1RAs, 84.4% had a diagnosis of diabetes with an average body mass index (BMI) of 36.2 kg/m2. Propensity-matched cohorts demonstrated that GLP-1RAs were associated with a reduced hazard of nonexudative AMD compared with metformin (HR, 0.68; 95% CI, 0.56-0.84), insulin (HR, 0.72; 95% CI, 0.58-0.89), and statins (HR, 0.70; 95% CI, 0.57-0.87). These findings were validated compared with aspirin and in an independent older cohort of patients. This significant reduction appeared after 3 years compared with metformin (HR, 0.69; 95% CI, 0.52-0.91), insulin (HR, 0.66; 95% CI, 0.5-0.87), and statins (HR, 0.67; 95% CI, 0.51-0.88). Time course results were validated using independent cohorts of propensity-matched patients taking medications for 3 years. Notably, GLP-1RAs also significantly reduced the risk of exudative AMD (HR, 0.70; 95% CI, 0.58-0.84) and primary open-angle glaucoma (HR, 0.58; 95% CI, 0.45-0.76) compared with insulin after 3 years. Use of GLP-1RAs showed no persistent impact on the risk of cataract formation or ocular hypertension compared with other medications. This study suggests that GLP-1RAs may reduce the risk of multiple age-related ocular diseases and the need for future prospective studies to validate these findings. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

5 November 2025 in Ophthalmology Retina
Verified
Journal Article
Closed access
KAKevin C. Allan
Kevin C. Allan
ECErin F. Cohn
Erin F. Cohn
SBSuraj Bala
Suraj Bala
SKSonia B. Kim
Sonia B. Kim
DKDavid C. Kaelber
David C. Kaelber
ARAleksandra V. Rachitskaya
Aleksandra V. Rachitskaya

7 June 2025 in American Journal of Ophthalmology Case Reports
Verified
Journal Article
Open access
LYL.H. Young
L.H. Young
SKS.B. Kim
S.B. Kim
JTJ.S. Takhar
J.S. Takhar
LSL.D. Sun
L.D. Sun
KWK.M. White
K.M. White
AOA.F. Omar
A.F. Omar
To present an atypical case of reactive infectious mucocutaneous eruption (RIME) in an adult patient attributed to primary adenoviral infection. This is a case describing the clinical course of a previously healthy 34-year old man who presented with acute onset urethritis and bilateral conjunctivitis. His left eye conjunctivitis progressed to pseudomembrane and symblepharon formation within days. His clinical course was marked by progressive worsening of urethritis and formation of mucus membrane ulceration and bullae even after antibiotic treatment and aggressive topical lubrication. He required admission and a multidisciplinary team made the diagnosis of adenovirus-induced RIME. He was treated with intravenous steroids and intravenous cyclosporine. He ultimately recovered with a good visual outcome. This case demonstrates a rare case of RIME in an adult triggered by an adenovirus infection. Multidisciplinary care is key to diagnosis and treatment.

26 April 2026 in Journal of Vitreoretinal Diseases
Verified
Journal Article
Closed access
ABAshvin Babu
Ashvin Babu
SKSonia B. Kim
Sonia B. Kim
DKDavid C. Kaelber
David C. Kaelber
KTKatherine E. Talcott
Katherine E. Talcott
RSRishi P. Singh
Rishi P. Singh
Purpose: To evaluate the short-term and long-term incidence and prevalence of retinal detachment (RD) and retinal tear, in addition to the relative risk (RR) of RD and retinal tear development following phacoemulsification. Methods: Patients who received bilateral phacoemulsification were identified through US-based electronic health records, with incidence and prevalence of RD and retinal tear reported. The second objective was a retrospective cohort design with greedy nearest neighbor 1:1 propensity score matching based on age, sex, race, ethnicity, and known risk factors for RD and retinal tear. Matched cohort analysis was reported as RR with 95% CI at 1 month, 3 months, 6 months, 1 year, 3 years, 5 years, and 10 years after phacoemulsification. Results: There were 742 337 patients identified. The prevalence of RD after phacoemulsification increased from 0.27% at 1 month to 1.41% at 10 years, while prevalence of retinal tear increased from 0.16% at 1 month to 0.97% at 10 years. The highest incidence of RD and retinal tear occurred between 1 and 3 years in 0.37% and 0.27% of patients, respectively. Among 731 362 matched patients, phacoemulsification was associated with a significantly increased risk of RD and retinal tear from 3 months to 10 years. The RR of retinal tear peaked at 1 year (1.54; 95% CI, 1.46-1.63), and the RR of RD peaked at 3 years (1.57; 95% CI, 1.52-1.62). Conclusions: Phacoemulsification is associated with sustained increases in RD and retinal tear risk even among patients matched for baseline risk. These findings underscore the need for long-term monitoring and education on potential complications.

11 July 2026 in American Journal of Ophthalmology
Verified
Journal Article
Open access
SKSonia B. Kim
Sonia B. Kim
MZMelody Y. Zhou
Melody Y. Zhou
KAKevin C. Allan
Kevin C. Allan
DKDavid . Kaelber
David . Kaelber
ABAmy S. Babiuch
Amy S. Babiuch
KTKatherine E. Talcott
Katherine E. Talcott
To investigate how exposure to GABAergic medications affects diabetic retinopathy (DR) development, progression, and complications. Retrospective clinical cohort study using multi-institutional electronic health record data (TriNetX, US Collaborative Network). Adults aged ≥ 18 years with type 2 diabetes mellitus with ophthalmology follow-up. Study cohorts had GABAergic prescription records for 6-months, 1-year, 3-years, or 5-years; control cohorts had no GABAergic prescriptions ever. Cohorts were propensity-score matched (PSM) on demographics, systemic comorbidities, common indications for GABAergic medications, and ophthalmic confounders. Outcomes included incident DR, progression from mild/moderate nonproliferative DR to severe nonproliferative DR, proliferative DR, or interventions required in advanced DR, and incident DR complications. Hazard ratio (HR) and 95% confidence intervals (CI); significance threshold < 0.9 or > 1.1. After successful PSM, there were 110 495 (6-months), 99 187 (1-year), 63 194 (3-years), and 40 810 (5-years) DR-naive study patients with the respective GABAergic prescription durations of interest. Compared to 109 603 DR-naive control patients, study patients demonstrated a significantly reduced HR for DR development at all time points from 6-months (HR 0.61, 95% CI 0.57-0.65) to 5-years (HR 0.81, 95% CI 0.77-0.85). Study patients (n = 14 644) with baseline mild/moderate nonproliferative DR had a significantly reduced hazard of progressing to severe nonproliferative DR, proliferative DR, or DR interventions with 6-months (HR 0.75, 95% CI 0.68-0.82) and 1-year (HR 0.69, 95% CI 0.73, 0.86) GABAergic exposure. Prescription for 6-months (HR 0.74, 95% CI 0.68-0.80) to 3-years (HR 0.80, 95% CI 0.84-0.86) was associated with a significantly reduced hazard for DR complications. Stratification by 4 specific medication indications consistently showed a reduced hazard for DR development with a 6-month prescription duration. GABAergic medication use, particularly short-term exposure, is associated with a reduced hazard of DR development, progression, and complications. These exploratory findings support a potential role of GABAergic modulation in diabetic retinal disease.

24 April 2026 in Journal of Vitreoretinal Diseases
Verified
Journal Article
Closed access
SKSonia B. Kim
Sonia B. Kim
ALAna Lopez
Ana Lopez
XGXinyu Gu
Xinyu Gu
HRHayden Reed
Hayden Reed
PEPriya S. Eppel
Priya S. Eppel
KTKatherine E. Talcott
Katherine E. Talcott
Purpose: To evaluate real-world differences in treatment frequency, appointment compliance, and visual outcomes among patients with DME or RVO whose eyes either remained on antivascular endothelial growth factor (anti-VEGF) therapy or were transitioned to slow-release intravitreal corticosteroid implants. Methods: This retrospective cohort study used electronic health records data (2012–2024) from the Cole Eye Institute to identify patients ages ≥18 years diagnosed as having DME or RVO, with included eyes divided into 2 groups: a study group receiving 6 months of anti-VEGF injections followed by 12 months of intravitreal corticosteroid implants, and a control group receiving anti-VEGF injections for the entire 18-month period. Descriptive analysis compared appointment burden and compliance, best-corrected visual acuity (BCVA), and central subfield thickness (CST) between the overall cohort, DME eyes, and RVO eyes. Results: Ninety-nine eyes (48 study, 51 control) were included. The study group had a higher number of scheduled appointments, despite receiving fewer injections after switching to intravitreal corticosteroid implants. Appointment compliance in the study group remained unchanged before and after switching. Over 18 months, BCVA remained stable, while CST decreased with anti-VEGF therapy but increased after eyes were switched to intravitreal corticosteroid implants. Conclusions: Although injection frequency was reduced in patients with DME or RVO receiving intravitreal corticosteroid implants, this treatment did not improve appointment compliance and was associated with less favorable anatomic outcomes. Nonetheless, intravitreal corticosteroid implants preserved visual function and may represent a viable alternative for patients with refractory disease or compliance barriers.